Latest Blogs

Dec 03, 2019
ASCO's delegation to the AMA HOD invites all ASCO members to share their thoughts and concerns concerning issues affecting the practice of oncology, as your input directly impacts the delegation's work.
Dec 03, 2019
When a patient is looking for the word "cure," anything else, especially if vague, is not enough. "No evidence of disease" leaves room for doubt but, importantly, also room for hope.
Dec 02, 2019
Dr. Omid Etemadi describes the evolution of integrated cancer care in the Philippines. 
Nov 26, 2019
What does the future of immuno-oncology look like? Dr. Elizabeth A. Mittendorf invites you to be part of the conversation at the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium in February.
Subscribe to this column

Clifford A. Hudis, MD, FACP, FASCO

Clifford A. Hudis, MD, FACP, FASCO, is the CEO of ASCO. Prior to this role, he served as chief of the Breast Medicine Service and an attending physician at Memorial Sloan Kettering Cancer Center and as a professor in the Department of Medicine at Weill Cornell Medical College. He is a past president of ASCO. His research interests include all areas of care related to breast cancer, with a focus on the development of novel systemic therapies and prevention interventions related to obesity and inflammation. Follow Dr. Hudis on Twitter @CliffordHudis.

Oct 16, 2019
Participants in ASCO's Advocacy Summit discuss the importance of being engaged with health policy to improve the lives of people affected by cancer.
Oct 04, 2019
About 42 million Medicaid patients do not have the guaranteed ability to participate in clinical trials.
May 20, 2019
Dr. Ward and I discuss the policies that public and private insurers use to control the use of anticancer drug therapies, such as prior authorization requirements, restrictive formularies, step therapy, or fail first requirements, and specialty specific tiers.
Mar 26, 2019
Dr. Sharpless joined me to talk about pediatric cancer research, clinical trial methodology, eligibility criteria, and more.
Mar 11, 2019
For many of us not a day has gone by without some reminder of Arti, but last week brought it all back into sharp focus as I was asked to talk about the role we at ASCO played in her career during a symposium in her honor.
Feb 07, 2019
Dr. Gottlieb discusses the FDA's efforts to increase overall efficiency by updating or modernizing aspects of our clinical trials conduct and expediting the end-to-end drug development process, as well as controlling the next generation of tobacco products.

Pages